Pulmonx LUNG
Pulmonx Q3 FY24: revenue $20.4M; diluted EPS −$0.36
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0001127537-24-000087
- Document
- 10-Q
Key figures from this report
These are the numbers Pulmonx reported for Q3 FY24, the quarter ended Sep 30, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Revenue$20.4MNo year-earlier figure tagged10-Q income statement, on EDGAR
- Net income−$14.1MNo year-earlier figure tagged10-Q income statement, on EDGAR
- Diluted EPS−$0.36No year-earlier figure tagged10-Q income statement, on EDGAR
- Cash and cash equivalents$63.3MNo year-earlier figure tagged10-Q balance sheet, on EDGAR
- Cash from operations−$7.2MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters
Similar companies
Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.
- Microbot Medical MBOT public float $96M, Jun 30, 2025
- TriSalus Life Sciences TLSI public float $112M, Jun 30, 2025
- Fonar FONR
- CVRx CVRX public float $112M, Jun 30, 2025
- LENSAR LNSR public float $113M, Jun 30, 2025
